SK Capital Partners' Buyout and Recapitalization of Apotex Leading to IPO
June 10, 2026
SK Capital Partners acquired control of Apotex from the Sherman estate in 2023, then reoriented the business with cost cuts, geographic focus, and portfolio acquisitions (including biosimilars and specialty drugs). Over the following three years, SK Capital and the Sherman family completed a debt-heavy leveraged buyout and extracted roughly $2 billion via dividends and share repurchases, culminating in Apotex’s IPO in June 2026.
- Buyers
- SK Capital Partners
- Targets
- Apotex Health Corp.
- Sellers
- Sherman estate
- Industry
- Pharmaceuticals
- Location
- Canada
- Transaction Type
- Recapitalization
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.